No Data
Buy Rating Affirmed on Theravance Biopharma Amid Strong Q1 Performance and Promising Pipeline Prospects
Theravance Biopharma | 10-Q: Quarterly report
HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $20 price target.
Earnings Call Summary | Theravance Biopharma(TBPH.US) Q1 2024 Earnings Conference
The following is a summary of the Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript:Financial Performance:Theravance Biopharma reported Q1 net sales of $55.2 million in partnership wi
Buy Rating Affirmed for Theravance Biopharma on Strong Portfolio Performance and Promising Drug Prospects
Analysts Have Conflicting Sentiments on These Healthcare Companies: Theravance Biopharma (TBPH), Voyager Therapeutics (VYGR) and Praxis Precision Medicines (PRAX)